Sunday 18 October 2026
Export APMD’s income statement to Excel — free account
Apnimed, Inc.
APMD
Apnimed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.5 million, up 380.1% from fiscal 2024. Insiders bought in the last twelve months.
17.76
0.49
−2.68%
Follow APMD
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | — | — | — |
+1 more TTM period Free account |
|
| 0.00% | — | — | — | ||
ROIC |
0.00% | 0.00% | 0.00% | — | |
Return on Tangible Assets |
64.01% | 0.00% | 0.00% | — | |
Average Days of Receivables |
2.15 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
(17.46) | 0.00 | — | 0.00 | |
Free Cash Flow |
(83.75) | — | — | — | |
| Other line items | |||||
Cash ROIC |
(109.87%) | 0.00% | 0.00% | — | |
Accounts Receivable Turnover |
0.00 | — | — | — | |
Accounts Payable Turnover |
0.00 | — | — | — | |
Inventory Turnover |
0.00 | — | — | — | |
Average Days of Payables |
375.65 | 0.00 | 0.00 | — | |
Days of Inventory on Hand |
0.00 | — | — | — | |
Tax Rate |
0.00 | — | — | — | |
Research and Development Expense of Revenue |
49.03% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
25.61% | — | — | — | |
Share Based Compensation of Revenue |
3.23% | — | — | — | |
Operating CF/Net income |
(0.88) | — | — | — | |
Depreciation/Fixed assets |
0.49 | 0.00 | 0.00 | — | |
Capex/Depreciation |
0.00 | — | — | — | |
Revenue per Share |
24.42 | 0.00 | — | 0.00 | |
Operating CF per Share |
(17.46) | 0.00 | — | 0.00 | |
Capex per Share |
0.00 | 0.00 | — | 0.00 | |
Capex to Sales |
0.00 | — | — | — |
Columns are period end dates · fundamentals updated 7 Oct 2026